JSR Life Sciences continues bid for CMO dominance with $400 million buy in Taiwan

20 December 2017

The life sciences arm of Japanese conglomerate JSR Corporation (TYO: 4185) has agreed to pay TW$12 billion ($400 million) to acquire Taipei-based Crown Bioscience International (Taipei: 6554).

Crown Bioscience is a global drug discovery and contract research organization (CRO) advancing candidates in oncology, inflammation, cardiovascular and metabolic disease. The firm has global reach, with offices in Europe, the USA and elsewhere.

The Japanese firm says it expects the company to achieve $90 million in revenue next year and EBITDA (earnings before interest, taxes, depreciation, and amortization) of $20 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK